VANTIVE US HEALTHCARE LLC

Lobbying for VANTIVE US HEALTHCARE LLC · Medical Technology Manufacturing

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$440,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Issues related to ESRD reimbursement H.R. 8319 - KIDNEY Remote Monitoring Act, Issues related to physician reimbursement for remote patient monitoring. H.R. 4441 - Patient Access to Innovative New Technologies Act, Issues related to sepsis device breakthrough designation.

Health Issues

Issues related to ESRD reimbursement H.R. 8319 - KIDNEY Remote Monitoring Act, Issues related to physician reimbursement for remote patient monitoring

Trade (domestic/foreign)

Issues related to tariffs including issues related to Section 232 investigation of medical devices. Issues related to medical technology trade.

Bills named in this filing 2

H.R. 8319
KIDNEY Remote Monitoring Act
H.R. 4441
Patient Access to Innovative New Technologies Act of 2025

Foreign interests disclosed 1

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

VANTIVE LIMITED

Ireland · Castlebar, Co. Mayo, F23 XR63 · owns 100% of the client · contributed $0

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.